Laura L Laslett|Sarah R. Kingsbury|Elizabeth M A Hensor|M.A. Bowes|Philip G. Conaghan
Effect of bisphosphonate use in patients with symptomatic and radiographic knee osteoarthritis: data from the Osteoarthritis Initiative
NIHR Leeds Musculoskeletal Biomedical Research Unit|University of Leeds|NIHR Leeds Musculoskeletal Biomedical Research Unit|University of Leeds|NIHR Leeds Musculoskeletal Biomedical Research Unit|University of Leeds|Chapel Allerton Hospital|NIHR Leeds Musculoskeletal Biomedical Research Unit
bisphosphonates reported beneficial effects treating osteoarthritis oa study examined effects bisphosphonate use symptoms structural progression knee oa participants nih osteoarthritis initiative cohortpeople typical oa trial entry criteria kl23 minimum joint space width 2550 mm pain 4 numeric rating scale classified bisphosphonate users 3 5 years n55 nonusers use preceding 5 years followup n268 annual data 4 years analysed using linear mixed modelling generalised estimating equationsbisphosphonate compliance 85 year 1 reducing 76 year 4 numeric rating scale pain scores significantly reduced among bisphosphonate users years 2 3 year 3 09 vs 22 p0004 though year 4 adjustment baseline pain analgesic use differences western ontario mcmaster universities osteoarthritis index womac pain disability scores reach statistical significance time point trend less joint space narrowing bisphosphonate users time year 4 051 vs 029 mm p006significant reduction numeric rating scale pain observed first 3 years bisphosphonate use diminution effects year 4 may reflect reduced compliance differences results obtained using numeric rating scale womac may reflect different constructs measured tools beneficial trend structural progression considered terms sample size